
News|Articles|September 26, 2023
How to mitigate risk for biologics during fill/finish manufacturing
Author(s)Emergent
As more biologics move through research and development, the demand for specialized aseptic fill/finish services has steadily climbed. Aseptic processing with the highest degree of sterility assurance, filling accuracy and quality is critical for high-value, small-batch therapies. Anything less impacts regulatory compliance, project timelines and—most importantly—patient safety. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5